PMID- 22718256
OWN - NLM
STAT- MEDLINE
DCOM- 20130321
LR  - 20120903
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 38
IP  - 6
DP  - 2012 Sep
TI  - Unfractionated heparin for the treatment of venous thromboembolism: best 
      practices and areas of uncertainty.
PG  - 593-9
LID - 10.1055/s-0032-1319770 [doi]
AB  - Nearly 100 years after its discovery, unfractionated heparin (UFH) remains a 
      widely used anticoagulant for the treatment of venous thromboembolism (VTE) and 
      several other thrombotic and prothrombotic conditions. Decades of experience and 
      investigation have contributed to our knowledge of this agent, but crucial 
      questions regarding its optimal use in clinical practice remain unanswered. This 
      review will critically examine the evidence for dosing and laboratory monitoring 
      of UFH in the management of VTE, and highlight areas of uncertainty and future 
      research.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Cuker, Adam
AU  - Cuker A
AD  - Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA. adam.cuker@uphs.upenn.edu
LA  - eng
GR  - K12HL087064/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20120620
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*administration & dosage
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Uncertainty
MH  - Venous Thromboembolism/blood/*drug therapy
EDAT- 2012/06/22 06:00
MHDA- 2013/03/22 06:00
CRDT- 2012/06/22 06:00
PHST- 2012/06/22 06:00 [entrez]
PHST- 2012/06/22 06:00 [pubmed]
PHST- 2013/03/22 06:00 [medline]
AID - 10.1055/s-0032-1319770 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2012 Sep;38(6):593-9. doi: 10.1055/s-0032-1319770. Epub 2012 
      Jun 20.